Clinical trials
Localized Prostate Cancer clinical trials
Below are recruiting localized prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 496 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06517719Recruiting
Real-world study of Pluvicto for advanced prostate cancer
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
Konstanz, Baden-WurttembergAges 18–99 - NCT05840484Recruiting
Monitoring study for men on active surveillance
This trial follows men with prostate cancer who choose “active surveillance” instead of immediate treatment. It tests whether careful tracking (including patient reports) can help manage cancer over time and guide decision-making.
Houston, TexasAges 18 years+ - NCT03769766RecruitingPhase 3
Curcumin to help keep low-risk prostate cancer from worsening
This study tests whether curcumin (a supplement made from turmeric) can prevent low-risk prostate cancer from progressing while you stay on active surveillance. If you qualify, you would take curcumin and be monitored closely with regular checkups.
Dallas, TexasAges 40–89 - NCT00588185Recruiting
Pet scans for advanced prostate or salivary gland cancer
This study uses special PET scans to get a detailed picture of prostate or salivary gland cancer that is getting worse. The scans may help doctors see the cancer more clearly and plan better treatment.
Basking Ridge, New JerseyAges Any age - NCT06825091RecruitingPhase 3
Comparing new SBRT to standard radiation for prostate cancer
This trial compares a newer, more precise type of radiation (adaptive SBRT) with standard image-guided radiation for prostate cancer. It aims to see if the newer approach is better at targeting the tumor while reducing side effects.
Toronto, OntarioAges 18 years+ - NCT07358806RecruitingPhase 1
Study of OCT-598 for advanced solid tumors
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Goyang-siAges 18 years+ - NCT06150417RecruitingPhase 2
Study of extra radiation for prostate cancer spread to few spots
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
New York, New YorkAges 18 years+ - NCT06666270RecruitingPhase 1
SYN818 for advanced solid tumors with DNA repair defects
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Zhengzhou, HenanAges 18 years+ - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Fayetteville, ArkansasAges 18 years+ - NCT06401980RecruitingPhase 2
Darolutamide for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
AarauAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Anchorage, AlaskaAges 18 years+ - NCT07550517RecruitingPhase 2
Radiation plus experimental nuclear medicine for high-risk prostate cancer
This trial tests whether adding an experimental radioactive drug called PSMA-617 to standard radiation and hormone therapy helps men with high-risk prostate cancer that hasn't spread beyond the pelvis. The radioactive drug targets cancer cells specifically.
Baltimore, MarylandAges 18 years+ - NCT07724028Enrolling by invitation
Nerve stimulation during robotic prostate surgery
This study tests whether stimulating specific nerves during robotic prostate surgery helps preserve erectile function. If you are scheduled for prostate surgery and have normal erections now, this research may help improve your recovery of erections afterward.
LjubljanaAges 18 years+ - NCT07678489Recruiting
Prostate surgery trial keeping the urethra intact
This trial tests a robot-assisted prostate surgery method that aims to preserve the entire urethra (the tube that carries urine out of the body) to help maintain continence. It's for men with low- to intermediate-risk prostate cancer who haven't had prior prostate treatments.
DüsseldorfAges 18 years+ - NCT06966778Recruiting
Oxybutynin to help bladder control after prostate surgery
This trial tests if the medicine Oxybutynin ER (a drug that helps relax the bladder) can help you regain bladder control sooner after robotic prostate surgery. Participants will be randomly assigned to receive either the drug or a placebo for a few weeks after surgery.
TaipeiAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Anchorage, AlaskaAges 18 years+ - NCT05649943Recruiting
New prostate cancer treatment plus local therapy for metastatic cases
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
Milan, LombardyAges 18 years+ - NCT06653452Recruiting
PET/MRI for rectal cancer treatment response
This study uses a special scan called PET/MRI to see how well treatment works for locally advanced rectal cancer before surgery. It may help doctors choose the best treatment plan for you.
Beijing, Beijing MunicipalityAges 18–75 - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT06881537RecruitingPhase 2
Chemo and targeted therapy before surgery for recurrent colorectal cancer
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
ShanghaiAges 18–75 - NCT05653453RecruitingPhase 3
Tumor treatment device plus chemo for locally advanced pancreatic cancer
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Harbin, HeilongjiangAges 18–75 - NCT06879041RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This study tests a new radioactive drug, [225Ac]-AZD2284, for men with prostate cancer that has spread and no longer responds to hormone therapy. The drug is designed to target cancer cells and deliver radiation directly to them, potentially slowing the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Santa Barbara, CaliforniaAges 18 years+
Hear when a new Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for localized prostate cancer?
- Yes. Clin2 currently lists 496 recruiting localized prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a localized prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a localized prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.